Using high resolution comparative genomic hybridization (CGH) array analysis of 235 ovarian cancers, we have narrowed the most frequent region of copy number increase in ovarian cancers to an ~3.2 MB wide region at 3q26.2. Real time PCR of genes within this region indicated that EVI1 (ecotropic viral integration site-1) and an intergenic MDS1/EVI1 fusion transcript were the most highly amplified transcripts within this region. Moreover, EVI1 is aberrantly spliced (Del190-515) in >90% of tumors. MDS1/EVI1 and EVI1 alter proliferation, motility, senescence, and signaling in ovarian epithelial cells. Further, increases in MDS1/EVI1 levels are associated with a good prognosis while EVI1Del190-515 was associated with a poor outcome. Thus, our data suggest that EVI1, MDS1/EVI1, and its splice forms play distinct roles during tumor initiation and progression depending on the cellular context. Patient outcome is likely dependent on the relative levels of the EVI1 splice variants. EVI1 has recently been implicated in cell survival and inhibition of transforming growth factor (TGF beta, TGF?) signaling by increasing PI3K (phosphatidylinositol-3-kinase) activity. Thus, we will test the hypothesis that the relative expression of the EVI1 proto-oncogene and its aberrantly spliced forms contributes to ovarian cancer initiation, progression, and drug responsiveness through differential effects on PI3K and TGF? signaling. We will test this hypothesis through the following three aims: 1) We will determine whether overexpression of aberrantly spliced forms of the proto-oncogene EVI1 contributes to ovarian cancer initiation, progression, and drug responsiveness. 2) We will determine whether EVI1 and its splice variants mediate different cellular effects through regulating the PI3K and TGF? signaling pathways. 3) We will test the hypothesis that splice variants of EVI1 predicts patient outcomes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA123219-05
Application #
8228088
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Spalholz, Barbara A
Project Start
2008-04-08
Project End
2013-02-28
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
5
Fiscal Year
2012
Total Cost
$307,535
Indirect Cost
$72,323
Name
University of Texas MD Anderson Cancer Center
Department
Biology
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Chaluvally-Raghavan, Pradeep; Zhang, Fan; Pradeep, Sunila et al. (2014) Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell 26:863-79
Kodigepalli, Karthik M; Dutta, Punashi S; Bauckman, Kyle A et al. (2013) SnoN/SkiL expression is modulated via arsenic trioxide-induced activation of the PI3K/AKT pathway in ovarian cancer cells. FEBS Lett 587:5-16
Dutta, Punashi; Bui, Tuyen; Bauckman, Kyle A et al. (2013) EVI1 splice variants modulate functional responses in ovarian cancer cells. Mol Oncol 7:647-68
Kodigepalli, Karthik M; Anur, Pavana; Spellman, Paul et al. (2013) Phospholipid Scramblase 1, an interferon-regulated gene located at 3q23, is regulated by SnoN/SkiL in ovarian cancer cells. Mol Cancer 12:32
Bauckman, K A; Haller, E; Flores, I et al. (2013) Iron modulates cell survival in a Ras- and MAPK-dependent manner in ovarian cells. Cell Death Dis 4:e592
Smith, D M; Patel, S; Raffoul, F et al. (2010) Arsenic trioxide induces a beclin-1-independent autophagic pathway via modulation of SnoN/SkiL expression in ovarian carcinoma cells. Cell Death Differ 17:1867-81
Nanjundan, Meera; Cheng, Kwai Wa; Zhang, Fan et al. (2008) Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis. Mol Oncol 2:164-81